{"date":"2026-09-10","count":10,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6666-2026-09-10-1843-p67uuk","company_id":"6666","company":"羅麗芬-KY","market":"上市","industry":"生技醫療","date":"2026-09-10","time":"18:43:15","subject":"公告本公司內部稽核主管異動","clause":"第8款","fact_date":"2026-09-10","cite_as":"公開資訊觀測站重大訊息：羅麗芬-KY（6666），2026-09-10 18:43，「公告本公司內部稽核主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4732-2026-09-10-1742-151rtx3","company_id":"4732","company":"彥臣","market":"興櫃","industry":"生技醫療","date":"2026-09-10","time":"17:42:57","subject":"代子公司御華生醫公告與國際AI臨床試驗公司QuantHealth Ltd.簽訂合約，進行NBM-BMX第二期臨床試驗策略規劃","clause":"第8款","fact_date":"2026-09-10","cite_as":"公開資訊觀測站重大訊息：彥臣（4732），2026-09-10 17:42，「代子公司御華生醫公告與國際AI臨床試驗公司QuantHealth Ltd.簽訂合約，進行NBM-BMX第二期臨床試驗策略」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4174-2026-09-10-1730-1ct39j7","company_id":"4174","company":"浩鼎","market":"上櫃","industry":"生技醫療","date":"2026-09-10","time":"17:30:37","subject":"本公司董事會決議擬向一美國大學授權單株抗體序列，以強化本公司次世代抗體藥物複合體產品線","clause":"第53款","fact_date":"2026-09-10","cite_as":"公開資訊觀測站重大訊息：浩鼎（4174），2026-09-10 17:30，「本公司董事會決議擬向一美國大學授權單株抗體序列，以強化本公司次世代抗體藥物複合體產品線」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4174-2026-09-10-1730-qx9uyx","company_id":"4174","company":"浩鼎","market":"上櫃","industry":"生技醫療","date":"2026-09-10","time":"17:30:14","subject":"本公司修訂115年員工認股權憑證發行及認股辦法","clause":"第11款","fact_date":"2026-09-10","cite_as":"公開資訊觀測站重大訊息：浩鼎（4174），2026-09-10 17:30，「本公司修訂115年員工認股權憑證發行及認股辦法」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6620-2026-09-10-1702-n87rq4","company_id":"6620","company":"漢達","market":"上櫃","industry":"生技醫療","date":"2026-09-10","time":"17:02:35","subject":"(補充公告115/08/06重大訊息)公告本公司新任商務長","clause":"第8款","fact_date":"2026-09-10","cite_as":"公開資訊觀測站重大訊息：漢達（6620），2026-09-10 17:02，「(補充公告115/08/06重大訊息)公告本公司新任商務長」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1762-2026-09-10-1538-16sohr8","company_id":"1762","company":"中化生","market":"上市","industry":"生技醫療","date":"2026-09-10","time":"15:38:17","subject":"本公司受邀參加元大證券舉辦之線上法人說明會","clause":"第12款","fact_date":"2026-09-16","cite_as":"公開資訊觀測站重大訊息：中化生（1762），2026-09-10 15:38，「本公司受邀參加元大證券舉辦之線上法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6917-2026-09-10-1526-vzqknm","company_id":"6917","company":"竟天","market":"興櫃","industry":"生技醫療","date":"2026-09-10","time":"15:26:20","subject":"本公司與博諾康源（北京）藥業科技有限公司簽訂合作意向書（MOU）","clause":"第8款","fact_date":"2026-09-10","cite_as":"公開資訊觀測站重大訊息：竟天（6917），2026-09-10 15:26，「本公司與博諾康源（北京）藥業科技有限公司簽訂合作意向書（MOU）」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6872-2026-09-10-1435-1nsksc0","company_id":"6872","company":"浩宇生醫","market":"上櫃","industry":"生技醫療","date":"2026-09-10","time":"14:35:39","subject":"本公司有價證券近期多次達公布注意交易資訊標準，故公告相關訊息，以利投資人區別暸解","clause":"第53款","fact_date":"2026-09-10","cite_as":"公開資訊觀測站重大訊息：浩宇生醫（6872），2026-09-10 14:35，「本公司有價證券近期多次達公布注意交易資訊標準，故公告相關訊息，以利投資人區別暸解」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4129-2026-09-10-1430-iwq3ul","company_id":"4129","company":"聯合","market":"上櫃","industry":"生技醫療","date":"2026-09-10","time":"14:30:23","subject":"公告本公司資訊安全長新任案","clause":"第8款","fact_date":"2026-09-10","cite_as":"公開資訊觀測站重大訊息：聯合（4129），2026-09-10 14:30，「公告本公司資訊安全長新任案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6617-2026-09-10-0135-1c4dk0t","company_id":"6617","company":"共信-KY","market":"上櫃","industry":"生技醫療","date":"2026-09-10","time":"01:35:39","subject":"代子公司天津紅日健達康醫藥科技有限公司公告，本公司治療肺癌產品PTS-302申請摩洛哥地區藥證查驗登記(NDA)已正式收件","clause":"第53款","fact_date":"2026-09-09","cite_as":"公開資訊觀測站重大訊息：共信-KY（6617），2026-09-10 01:35，「代子公司天津紅日健達康醫藥科技有限公司公告，本公司治療肺癌產品PTS-302申請摩洛哥地區藥證查驗登記(NDA)已正式收」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}